Inoperable NSCLC is associated with poor prognosis. Response to chemotherapy and survival depend on biologic properties of tumor. We asked a question if serum (s) Cyfra 21-1 and CEA estimation is helpful in predicting response to chemotherapy and survival in this group of patients (pts).
Tumor markers were measured before treatment in 162 NSCLC pts: 93 stage IIIa+b, 69 stage IV. All the patients received cisplatin based chemotherapy. The response to treatment assessed before the third course was: PR in 46 pts, MR in 33, SD in 40 and PD in 43.
sCyfra 21-1>3.3 ng/ml was found in 89(52%) of pts and correlated significantly with disease extension (DE) and performance status (PE). PD was more frequent in the group of 23 pts with Cyfra 21-1>10 ng/ml than in remaining pts. sCEA>3 ng/ml was found in 74(46%) of pts and correlated with PS but not with DE and type of response to treatment. PS was the only predictor of type of response to treatment in multivariate analysis. DE, PS and sCEA>3 ng/ml were found to be a negative prognostic factors in multivariate analysis. sCyfra 21-1>10 ng/ml was a prognostic indicator in univariate analysis only.
sCEA but not sCyfra 21-1 is an independent prognostic factor in advanced NSCLC.
We recommend sCEA measurement before treatment as an additional predictor of life expectancy in advanced NSCLC.
M. Szturmowicz, None.